Clinical Trial Update: Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. [Phase 2]

View source ↗

Summary

Phase 2 study assessing immunogenicity and safety of Hipra's booster vaccination in adults previously vaccinated with an adenovirus COVID-19 vaccine; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2 Acute Respiratory Disease

Drugs mentioned

• HIPRA candidate booster vaccination

Snippet

Sponsor: Hipra Scientific, S.L.U | Conditions: COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Status: COMPLETED